VKTX shares have gained 30% in the trailing 52 weeks. However, it has declined 60% since hitting a record peak in September last year.
Investors will be looking forward to any updates regarding the ongoing research on nonalcoholic steatohepatitis (NASH), a liver disease. Last month, Viking shares had jumped 6% after it was reported that rival Gilead Sciences’ (GILD) NASH candidate failed to meet its primary endpoint.
The stock once again received a bump when peer firm Intercept Pharmaceuticals (ICPT) produced positive topline results from the phase 3 study for its NASH drug. According to DelveInsight, the NASH market will experience significant annual growth over the 2016-2028 study period, as major-market sales increase up to $30.1 billion by 2028.
The stock has a 12-month average price target of $23, which represents a 193% upside from the last close. Hence the scope for a rally is high if the California-based firm pleases investors.